Search research articles
Contact Us
Filters
Showing results (211-220 of 312) with videos related to
Page
of 32
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 2, 2026
Phase 1b trial of Bavdegalutamide (ARV-110) in combination with Abiraterone for metastatic prostate cancer
Martin Smoragiewicz, Alice Bernard-Tessier, Mark Linch, et al.
European Urology
|
July 13, 2016
Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302
Johann S de Bono, Matthew R Smith, Fred Saad, et al.
The Prostate
|
February 17, 2015
Safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: expanded access in North America
Anthony M Joshua, Neal D Shore, Fred Saad, et al.
European Urology
|
March 19, 2017
Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302
Matthew R Smith, Fred Saad, Dana E Rathkopf, et al.
European Urology Oncology
|
June 12, 2024
Expert Consensus Recommendations on the Management of Treatment-emergent Adverse Events Among Men with Prostate Cancer Taking Poly-ADP Ribose Polymerase Inhibitor + Novel Hormonal Therapy Combination Therapy
Neal D Shore, Michael S Broder, Pedro C Barata, et al.
Bladder Cancer (Amsterdam, Netherlands)
|
July 12, 2024
Reduced Dose Intravesical Bacillus Calmette-Guérin: Why It Might Not Matter
Ashish M Kamat, Niyati Lobo, Seth P Lerner, et al.
Future Oncology (London, England)
|
January 8, 2024
CREST: phase III study of sasanlimab and Bacillus Calmette-Guérin for patients with Bacillus Calmette-Guérin-naïve high-risk non-muscle-invasive bladder cancer
Gary D Steinberg, Neal D Shore, Joan Palou Redorta, et al.
European Urology
|
May 13, 2023
The Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Oligometastatic Hormone-sensitive Prostate Cancer: A Post Hoc Analysis of ARCHES
Andrew J Armstrong, Taro Iguchi, Arun A Azad, et al.
NEJM Evidence
|
February 6, 2024
Enzalutamide and Quality of Life in Biochemically Recurrent Prostate Cancer
Stephen J Freedland, Martin Gleave, Ugo De Giorgi, et al.
The New England Journal of Medicine
|
June 1, 2026
PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate Cancer
Neeraj Agarwal, Nobuaki Matsubara, Arun A Azad, et al.
Page
of 32
Search research articles
Search
Showing results (211-220 of 312) with videos related to
Sort By:
Page
of 32
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 2, 2026
Phase 1b trial of Bavdegalutamide (ARV-110) in combination with Abiraterone for metastatic prostate cancer
Martin Smoragiewicz, Alice Bernard-Tessier, Mark Linch, et al.
European Urology
|
July 13, 2016
Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302
Johann S de Bono, Matthew R Smith, Fred Saad, et al.
The Prostate
|
February 17, 2015
Safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: expanded access in North America
Anthony M Joshua, Neal D Shore, Fred Saad, et al.
European Urology
|
March 19, 2017
Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302
Matthew R Smith, Fred Saad, Dana E Rathkopf, et al.
European Urology Oncology
|
June 12, 2024
Expert Consensus Recommendations on the Management of Treatment-emergent Adverse Events Among Men with Prostate Cancer Taking Poly-ADP Ribose Polymerase Inhibitor + Novel Hormonal Therapy Combination Therapy
Neal D Shore, Michael S Broder, Pedro C Barata, et al.
Bladder Cancer (Amsterdam, Netherlands)
|
July 12, 2024
Reduced Dose Intravesical Bacillus Calmette-Guérin: Why It Might Not Matter
Ashish M Kamat, Niyati Lobo, Seth P Lerner, et al.
Future Oncology (London, England)
|
January 8, 2024
CREST: phase III study of sasanlimab and Bacillus Calmette-Guérin for patients with Bacillus Calmette-Guérin-naïve high-risk non-muscle-invasive bladder cancer
Gary D Steinberg, Neal D Shore, Joan Palou Redorta, et al.
European Urology
|
May 13, 2023
The Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Oligometastatic Hormone-sensitive Prostate Cancer: A Post Hoc Analysis of ARCHES
Andrew J Armstrong, Taro Iguchi, Arun A Azad, et al.
NEJM Evidence
|
February 6, 2024
Enzalutamide and Quality of Life in Biochemically Recurrent Prostate Cancer
Stephen J Freedland, Martin Gleave, Ugo De Giorgi, et al.
The New England Journal of Medicine
|
June 1, 2026
PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate Cancer
Neeraj Agarwal, Nobuaki Matsubara, Arun A Azad, et al.
Page
of 32